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Microbial point-of-care testing (POCT) has potential to revolutionise clinical care. Understanding 
prognostic value of microbes identified from the upper respiratory tract (a convenient sampling site) 
is a necessary first step to understand potential for upper respiratory tract POCTs in assisting 
antimicrobial treatment decisions for respiratory infections (RTIs).  
Objectives 
To investigate the relationship between upper respiratory tract microbial detection and disease 
prognosis, including effects of antimicrobial use. 
Data sources 
MEDLINE and Embase databases. 
Study eligibility criteria  
Quantitative studies reporting microbiological and prognostic data from patients of all age groups 
presenting with RTI. 
Participants 
Patients presenting to healthcare or research settings with RTI. 
Interventions  
Upper respiratory tract swab. 
Methods 
Systematic review and meta-analysis.  
Results 
Searches identified 5156 articles, of which 754 were duplicates and 4258 excluded on title or 
abstract. 144 full texts were screened;21 articles retained. Studies reported data for 15 microbes 
and 26 prognostic measures (390 potential associations). 107 (27%) associations were investigated 
statistically, of which 38 (36%) were significant. Most studies reported only prognostic value of test 
positive results. Meta-analyses suggested hospitalisation duration was longer for patients with 
respiratory syncytial virus than adenovirus and influenza, but significant heterogeneity was observed 
between studies.  
Conclusions 
A quarter of potential prognostic associations have been investigated. Of these, a third were 
significant, suggesting considerable potential for POCT. Future research should investigate 
prognostic value of positive and negative tests, and interactions between test result, use of 








Point-of-care tests used by primary care clinicians to target antimicrobial prescribing could 
revolutionise the treatment of respiratory tract infections (RTI), improving patient outcomes and 
reducing drug side-effects and antimicrobial resistance. Primary care clinicians are responsible for the 
majority of human antibiotic use in the UK, US and Europe. Paediatric RTI is the most common 
presentation managed by primary care physicians.1 2 Antibiotics are prescribed at up to 67% of RTI 
consultations,3 yet there is strong evidence that a large proportion of these prescriptions are 
unnecessary.4 5 Antibiotic overprescribing has been partially attributed to uncertainty described by 
clinicians in identifying patients who may subsequently develop serious illness, and require hospital 
intervention.6 Policy makers, primary care clinicians and the research community are calling for 
evidence to help differentiate patients who would benefit from antimicrobials from those who would 
not.5 7 8 
There is currently no way for a primary care clinician to distinguish viral from bacterial aetiology for 
respiratory infections in a timely manner. The burden placed on primary care means that evidence-
based algorithms and tests are actively being sought; for example, an algorithm to identify children at 
risk of hospitalisation has recently been developed in a large observational study.9 However this 
algorithm does not differentiate bacterial from viral infection. Additionally, C-reactive protein blood 
testing to target prescribing in adults and children is being investigated 10 but is not routinely used in 
the UK. A third possible strategy, and the subject of this review, is to rapidly test respiratory 
microbiological samples. Point-of-care test technology is rapidly developing: test devices are now able 
to detect common respiratory tract microbes in 20 minutes to two hours, 11 and could therefore be of 
value in primary care.  
Upper respiratory tract samples are acceptable to patients and are easily obtained in primary care.9 
Recent evidence suggests that specific microbes are weakly associated with clinical characteristics of 
children with RTI at presentation to primary care, and may be aetiological.12 However, the association 
between the detection of these microbes and: (i) patient prognosis; and (ii) patient response to 
antimicrobial treatment is unknown. If detection of specific microbes from the upper respiratory tract 
was associated with response to antimicrobial treatment, tests for these microbes could be used to 
target antimicrobial prescribing.  
Research question 
To determine whether specific microbes detected from the upper respiratory tract are associated with 
the prognosis in patients of all ages presenting to all healthcare services with RTIs. Secondary 
questions are whether prognosis is affected by prescription of antimicrobials or the resistance status 







Studies eligible for inclusion were peer-reviewed, quantitative studies reporting microbiological and 
prognostic data from patients of all age groups presenting to a healthcare service or research team in 
an Organisation for Economic Co-operation and Development member country, with diagnosis or 
symptoms of RTI. Studies recruiting from primary care, secondary care, and community settings such 
as hospital outpatient or community research clinics were included. Studies were excluded where 
participants were recruited solely from intensive care or from a population with a high prevalence of 
pre-existing chronic disease or immune incompetence. Full inclusion and exclusion criteria are given 
in Table 1. 
Search strategy  
Our search strategy was designed to identify studies and systematic reviews that reported the 
relationships between microbes sampled from the upper respiratory tract in patients with respiratory 
tract infection, and prognostic outcomes. MEDLINE and Embase databases were searched using the 
OVID platform to 15 March 2018.  
The MEDLINE search strategy is presented in Appendix 1 and used combinations of MeSH (Medical 
Subject Headings) terms and text words for clinical diagnoses of respiratory infection; 20 different 
microbes implicated in respiratory tract infection (identified by consultant microbiologists and used in 
previously published work);13 and MeSH terms and text words for prognosis. The search excluded 
papers focusing on cystic fibrosis and tuberculosis. This search strategy was developed, extensively 
tested and refined using an iterative process with input from the University of Bristol subject librarian 
and search expert, and was subsequently adapted for use in Embase. The search was limited to 
humans, and no time restrictions were applied. Reference lists of all included full-text articles were 
also screened. 
Study selection 
Titles and abstracts of all identified studies were assessed for eligibility by one author (HT) and those 
which did not fulfil the inclusion/ exclusion criteria were excluded. Full-text copies of included articles 
were independently reviewed. Dual screening was performed for 20% of all records by three authors 
(IL, AB and CH) and eligibility disagreements resolved by discussion. 
Data extraction and quality assessment 
Data were extracted from full texts using a purpose-designed Access form. Descriptive variables were: 
country of recruitment; study setting (e.g. primary/ secondary care), study design, anatomical 
respiratory tract sampling location, laboratory methods, microbes identified, diagnoses of 
participants, number of participants, participant age inclusion criteria, type of prognostic outcomes 
reported, and whether results were stratified by antibiotic prescribing or consumption. Outcome data 
extracted were any measure of prognosis, including but not limited to symptom duration, 
hospitalisation and length of hospital stay. The number of outcomes reported by studies for each 
microbe, and any association found between microbe and outcome, was recorded and reported in a 
‘vote count’ table. Where the same outcome was reported for the same microbe by three or more 
studies, with means and standard deviations, random-effects meta-analysis was carried out using 
STATA (Stata Statistical Software: Release 13. College Station, TX: StataCorp LP) using the ‘metan’ 








Our search identified 5156 articles of which 754 were duplicates (Error! Reference source not found.). 
Of the 4402 remaining, 3829 were excluded on the basis of title and a further 429 on the basis of 
abstract. Full texts of 144 articles were screened and 21 were eligible for inclusion in the review.  
Study characteristics and microbiological data 
Characteristics of the 21 studies included in this review are summarised in Table 2. The most common 
recruitment setting was hospital inpatients (13 studies; 62%), followed by hospital outpatient/ 
community research clinics or primary care centres (five studies; 24%) and emergency departments 
(two studies; 10%). One study recruited in both primary care centres and an emergency department. 
The majority of studies (16; 76%) recruited only children, with eight recruiting children aged less than 
two years.  
Most studies used a prospective observational design (17, 81%). Several upper respiratory sampling 
methods were used: nasopharygeal wash/ aspirate (13 studies, 62%); nasopharyngeal swabs (4 
studies, 19%); combinations of nasal, throat, nasopharyngeal swabs and aspirates (three studies, 
14%); and a rhino-pharyngeal swab (one study, 5%). Laboratory methods also varied between studies, 
with 11 (52%) using polymerase chain reaction techniques, 3 (14%) using immunofluorescence, and 
the remainder using mixed/ other methods.  
Data were reported for 15 microbes / groups of microbes, including four bacteria, 10 viruses, and a 
combined Influenza A/B category. A full list of reported microbes is given in Table 4. The most data 
were reported for RSV (15 associations with prognosis investigated), rhinovirus (6) and influenza (6). 
The majority (13, 62%) reported data only for participants who were positive for the microbe(s) of 
interest; there is therefore a paucity of ‘control’ data from participants without detected microbes. 
None of the studies quantified microbial load, and no study reported outcomes stratified by antibiotic 
consumption or antimicrobial resistance. 
Quality assessment is summarised in Table 3.  No study had high risk of bias in the domain assessing 
attrition. The domain assessing confounding showed high risk of bias, commonly because studies 
measured limited numbers of microbes such that results could have been confounded by the presence 
of an untested microbe. High risk of bias was observed in three other domains for at least one study. 
Three studies had low risk of bias in all domains; 10 had high risk of bias in at least one domain. 
Outcomes  
Prognostic outcomes are listed in Table 4, which shows a ‘vote count’ of associations examined 
between reported microbes and outcomes, and whether associations were reported by the primary 
study authors as statistically significant. In total, 26 differently measured outcomes were reported, 
the majority of which fell into three categories: (i) hospitalisation duration (nine measures); (ii) 
symptom duration (eight measures); and (iii) healthcare use (six measures).  
 
The most commonly reported outcome was duration of hospitalisation, which was reported by at 
least one study for all microbes (Table 4). Symptom duration was reported using at least one 
measure for 10/15 microbes, and healthcare use was reported using at least one outcome for 9/15 
microbes. 
 
Relationship between microbes and prognosis 
The 26 outcome and 15 microbe categories reported in Table 4 give a total of 390 possible 




associations reported by all studies. There were an additional five microbes for which we sought 
data, but identified no relevant studies.  
 
Statistical tests were used to assess relationships between microbe detection and outcomes for 
107/134 outcomes. These were reported by the study authors to be statistically significant (p<0.05) 
in 38/107 (36%). Twenty seven associations were reported in which the authors did not use 
statistical tests, but reported raw data. 
 
Due to the diversity of outcome measures reported, opportunities for meta-analyses were limited. 
We considered use of methods designed for synthesis of diversely reported outcomes including the 
albatross plot,15 but were unable to proceed due to insufficient primary data.  
  
Meta-analysis was possible for duration of hospitalisation. Means and standard deviations were 
provided by seven studies for RSV and three for adenovirus. Data were also available from three 
studies, pooling results for influenza A and B. A forest plot for these analyses is given in Figure 2. 
Significant heterogeneity was observed for all three pooled estimates and as such they should be 
interpreted with caution. 
 
One additional study (Laundy et al16) provided mean duration of hospitalisation for patients with RSV 
and influenza A, but could not be included in the meta-analysis as no standard deviation was 
reported. When compared with the results of the meta-analysis, the mean duration of 
hospitalisation for RSV (2.2 days) and influenza A (6.0 days) do not fall within the confidence 
intervals for the pooled estimates. However, the Laundy study was small, with eight participants 
identified with influenza A and nine with RSV, which means the contribution of the study, if 
incorporated into meta-analysis, would be low. 
 
It was not possible to examine whether antibiotic prescribing or antimicrobial resistance status 






Summary of main findings 
Our review highlights a paucity of evidence for the prognostic value of upper respiratory tract 
microbes: of the potential 390 possible associations only 27% have been investigated. That said, of 
those that have been tested, 36% were reported as significant.  
Our meta-analysis suggests hospitalisation duration is longer for patients with respiratory syncytial 
virus than adenovirus and influenza, but we found significant heterogeneity between studies. This is 
likely to result from the differences in study recruitment setting, country, laboratory methods and 
participant diagnoses described in Table 2. 
Findings in relation to existing literature 
Previous work has demonstrated that some specific bacteria and viruses are present more often in 
the throats of children with acute cough and RTI than in asymptomatic children, 12 13 17 providing 
some evidence that acute cough alters the flora of the upper respiratory tract and microbes 
detected there may be aetiological. However, we have also demonstrated here that there is an 
absence of evidence as to whether targeting antimicrobial treatment to the results of upper 
respiratory tract microbial testing would lead to improved outcomes.  
Strengths and weaknesses 
This review was rigorously conducted and reported according to Cochrane and PRISMA guidelines. 14 
18  The search strategy was designed by subject experts and the quality of included studies assessed 
using the appropriate QUIPS tool.14  We used a ‘vote count’ table as the most succinct way to 
present the overall results of the review, though this does mean that small studies lend as much 
visual weight to results as their larger counterparts.19 
It is possible that by restricting inclusion, we could have reduced the heterogeneity between studies. 
However, doing so would have limited our results to a focused population or outcome, limited 
opportunities for meta-analysis even further, and reduced generalisability of any findings to the 
broader population.  
26 different prognostic measures were identified in the literature. At present, no core outcome set 
exists for RTI, which leads different studies to measure slightly different outcomes. We aimed to 
capture all relevant published data in this review, yet had studies (and hence this review) focused on 
an internationally agreed set of outcomes, it is likely that the percentage of potential associations 
investigated would have been higher. The large number of associations reported is both a finding in 
itself, and a limitation of this work.  
We were unable to assess the impact of antimicrobial use or antimicrobial resistance on prognosis 
for patients with/ without bacterial detection as studies did not report results stratified by antibiotic 
use or resistance status.  
Clinical and research implications 
Our results suggest significant potential for using upper respiratory tract microbes as the target of 
future POCT studies.  
The currently un-investigated microbial-prognosis associations should be urgently subjected to 
rigorous research, which should include assessments of the impact of microbial load, antibiotic use, 
resistance status, the value of negative results. Despite a rigorous search, we identified few studies 
which reported prognostic data for bacterial identification, with the majority of data reporting viral 




minimise confounding by the presence of an untested microbe, and more studies are needed in the 
primary care setting.  
Conclusions 
A quarter of potential prognostic associations have been investigated, and of these a third were 
significant, suggesting considerable potential for POCT. Future research should investigate the 
prognostic value of both positive and negative tests in both primary and secondary care, and look for 
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Table 1: Inclusion and exclusion criteria 
Inclusion criteria 
1. Peer-reviewed quantitative studies reporting individual-level microbiology from upper 
respiratory tract samples  
2. Participants presenting to a healthcare service or research team with a respiratory tract 
infection  
3. Studies reporting raw data cross-tabulating one or more prognostic outcomes (e.g. illness 
duration, hospitalisation) against RTI-related upper respiratory tract microbes  
 
Exclusion criteria 
1. Microbiology results from lung, blood, urine or faecal samples  
2. Microbiology presented as pooled data (as opposed to by individual microbe) 
3. Study participants recruited from a population with a high prevalence of pre-existing 
disease or immune incompetence in whom microbe sampling / detection may differ from 
wider population 
4. Studies of nosocomial infections 
5. Full text not available in English 





































use?   
Bambe
rger 
2012 21 Israel Inpatient 
Prospective 
observational 366 <24mo Acute bronchiolitis NPA PCR RSV 
Duration of hospitalisation: 
categories <3d, 4-7d, 7+d; 
mean PICU stay; 
supplemental oxygen 
duration <3d: yes/no No No 
Bennet
t 2007 
22 USA A&E 
Prospective 








Duration of illness: median; 












RSV and flu A&B 
(combined)  
Duration of fever & duration 
of hospitalisation: mean (SD), 






observational 1031 <18y 
Febrile upper respiratory 
tract infection NPA 
Immunoflu
orescence RSV, PIV, Adv 
Duration of hospitalisation: 










observational 774 Any age 
Laboratory-confirmed 




swab RT-PCR Flu A & B 
Hospitalisation: yes/no; illness 
duration split by age group: 









case–control 414 Adult ‘Airway infections’ NPS PCR M. pneumoniae 
Admission to hospital (yes/ 






observational 404 0-16y 
Lower respiratory tract 
infections NPA RT-PCR 
RSV, RV, HBoV, 
adenoviruses 
Duration of hospitalisation: 
median No No 
Garcia-
Garcia 
2017 28 Spain Inpatient 
Prospective 
observational 3906 <14y 
Acute respiratory tract 
infection NPA RT-PCR 
HMPV, RSV, RV, 
HBoV, adeno 
Duration of fever and 
duration of hospitalisation: 
mean (SD) No No 
Güllü 
2017 29 Turkey Inpatient 
Prospective 







Duration of hospitalisation: 
mean and SD Yes No 
Iwane 
2011 30 USA Inpatient 
Prospective 
observational 1867 <5y 
Acute respiratory tract 
infection 
NS & 
TS RT-PCR RV 
Hospital stay >3d: yes/no; 
duration of hospitalisation: 























































Hospitalisation: yes/no; ED 
presentation: yes/no; 
symptom duration: mean and 






observational 4181 Any age 
‘Respiratory tract 
infections’ NPA RT-PCR 
HCoV, Flu A & B, 
Adv, 
parainfluenzaviru
ses, RSV, hMPV 
Duration of fever and 
duration of hospitalisation: 
mean and SD No No 
Laundy 
2003 16 UK 
Primary 
care centre  
& A&E 
Prospective 






PCR RSV, influenza A 
Duration of hospitalisation, 
fever and illness duration: 
median, mean and range No  No 
Mansb
ach 
2008 33 USA A&E 
Prospective 
observational 277 <2y Bronchiolitis NPA PCR RSV, RV 
Symptom duration: median, 
IQR; relapse within two 
weeks: yes/no; days of activity 
limitation post hospital visit: 
median (IQR) No  No 
Margu
et 
2009 34 France Inpatient 
Prospective 
observational  209 1m–1y 
First episode acute 
bronchiolitis NPA RT-PCR RSV, RV, hMPV 
Duration of hospitalisation: 
median (IQR)  Yes No 
Mullins 





observational 60 Adult Influenza-like illness NPS PCR Influenza 
Days off school/work: mean 
(CI) Yes No 
Palomi
no 
2004 36 Chile Inpatient 
Prospective 
observational 117 <2y 




Duration of hospitalisation: 
median No No 
Resch 
2011 37 Austria Inpatient  
Retrospective 





orescence RSV & influenza 
Duration of hospitalisation: 
mean (SD); supplemental 
oxygen treatment duration No No 
Shaikh 
2014 38 USA Outpatient 
Prospective 
observational  206 2-12y Acute sinusitis NPS Culture 
S. pneumoniae, 
M. catarrhalis, H. 
influenzae 
Days to symptom resolution: 
median Yes No 
Tsolia 





case review 636 <1y Bronchiolitis NPW 
Immunoflu
orescence RSV 
Duration of hospitalisation: 
mean (SD); intensive care 





































Kong Inpatient  
Prospective 
observational 475 <5y 







Adv, influenza A 




Duration of hospitalisation: 
categories: <2d, 3-4d, >5d, 
median (IQR) No No 
Abbreviations: d: days; w: weeks; mo: months; y: years; NPA: nasopharyngeal aspirate; PCR: polymerase chain reaction; RT-PCR: reverse-transcriptase PCR; hMPV: human metapneumovirus; 
HBoV: human bocavirus; SD: standard deviation; IQR: interquartile range; RSV: respiratory syncytial virus; RV: rhinovirus; NPS: nasopharyngeal swab; A&E: accident and emergency 
department; GP: general practice; NP: nasopharyngeal; ELISA: enzyme-linked immunosorbent assay; HCoV: coronaviruses; Adv: adenovirus; PIV: parainfluenzavirus; NS: nasal swab; TS: throat 
swab; ED: emergency department; NPW: nasopharyngeal wash; PICU: paediatric intensive care unit.  
 















Lau 2006 2 1 1 2 3 2 
Shaikh 2014 1 1 1 1 3 1 
Laundy 2003 1 1 2 2 2 3 
Lambert 2007 1 1 1 2 1 2 
Mansbach 2008 1 1 1 1 3 2 
Bennet 2007 1 1 2 1 2 2 
Chan 2007 1 1 2 1 3 2 
Garcia-Garcia 2017 1 1 1 1 2 1 
Marguet 2009 1 1 1 1 1 1 
Tsung 2010 2 1 1 1 2 2 
Franz 2010 1 1 1 1 1 1 
Lambert 2007 1 1 1 1 1 1 
Palomino 2004 1 1 3 1 2 1 
Tsolia 2003 2 1 2 2 3 1 




Resch 2011 1 1 2 2 2 1 
Foshaug 2015 1 1 1 1 3 1 
Mullins 2011 1 1 2 1 2 1 
Iwane 2011 1 1 1 1 3 1 
Cohen 2015 2 1 1 1 1 1 
Gullu 2017 1 1 2 1 3 1 
Bamberger 2012 1 1 1 1 2 1 






Table 4: Vote count’ of associations sought between clinical outcomes and microbes reported by studies  
 
Key: Numbers report the number of studies seeking an association between a prognostic outcome 
measure and a microbe detected from the upper respiratory tract. Green number: statistically 
significant association reported. Red: Non-significant association reported. Black: statistical tests not 











Appendix 1: MEDLINE search strategy (subsequently adapted for use in EMBASE) 
 
1 Respiratory Tract Infections/ or bronchitis/ or exp bronchiolitis/ or Common Cold/ or Influenza, 
Human/ or exp Laryngitis/ or exp Pharyngitis/ or exp Pneumonia/ or exp Rhinitis/ or exp Sinusitis/ 
or whooping cough/ 
2 (sinusitis or pharyngitis or laryngitis or bronchitis or bronchiolitis or flu or influenza or rhinitis or 
RTI or pneumonia cough or pertussis or croup or bronchopneumonia).ti,ab. 




7 exp historical article/ 
8 Anecdotes as topic/ 
9 comment/ 
10 case report/ 
11 (letter or comment$).ti. 
12 animals/ not humans/ 
13 exp Animals, Laboratory/ 
14 exp Animal Experimentation/ 
15 exp Models, Animal/ 
16 exp rodentia/ 
17 (rat or rats or mouse or mice or bovine).ti. 
18 or/4-17 
19 respiratory syncytial viruses/ or respiratory syncytial virus, human/ 
20 Rhinovirus/ 
21 Streptococcus pneumoniae/ 
22 exp Haemophilus influenzae/ 
23 "Moraxella (Branhamella) catarrhalis"/ 
24 Mycoplasma pneumoniae/ 
25 Chlamydophila pneumoniae/ 
26 exp Staphylococcus aureus/ 
27 Adenoviridae/ 
28 exp influenzavirus a/ or exp influenzavirus b/ 
29 bordetella parapertussis/ or bordetella pertussis/ 
30 (colonization or colonisation).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms] 
31 ("Haemophilus influenza$" or "hemophilus influenza$" or "h.influenza$" or RSV or "respiratory 
syncytial virus$" or coronavirus or adenovirus or parainfluenzavirus or parainfluenza virus or 
metapneumovirus or metapneumonovirus or rhinovirus or bordetella or "s.aureus" or "s. aureus" 
or staph aureus or Staphylococcus aureus or Streptococcus pneumonia$ or strep pneumonia$ or 
"s.pneumonia" or "s.pneumoniae" or "s. pneumonia" or "s. pneumoniae" or "m.pneumonia" or 
"m.pneumoniae" or "m. pneumonia" or "m. pneumoniae" or mycoplasma pneumonia$ or ((group 
a or beta hemolytic) adj2 streptococc$) or chlamydia pneumonia$ or "c.pneumonia" or 






34 "Predictive Value of Tests"/ 
35 duration.ti,ab. 
36 or/33-35 
37 exp *Genomics/ 
38 exp *Sequence Analysis, DNA/ 
39 exp *Tuberculosis/ 
40 tuberculosis.ti. 
41 ("intensive" or "vaccin*").m_titl. 
42 ("ventilat*" or "cystic" or "CF").mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary concept word, rare 
disease supplementary concept word, unique identifier, synonyms] 
43 limit 42 to abstracts 
44 or/37-41 
45 18 or 43 or 44 
46 3 and 32 and 36 
47 46 not 45 
Nb: the inclusion of a forward slash (/) after a word indicates a Medical Subject Heading (MeSH) 
search term 
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